Navigation Links
Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Date:6/2/2010

s or implied discussions regarding potential new indications or labeling for Afinitor or regarding potential future revenues from Afinitor. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Afinitor to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Afinitor will be approved for any additional indications or labeling in any market. Nor can there be any guarantee that Afinitor will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Afinitor could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or
'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- The ... by universal healthcare coverage and good access to ... population and its associated disease burden, well-defined regulatory ... introduction of a new manufacturing policy will drive ... However, a focus on generic substitution and price ...
(Date:9/2/2014)... , Sept. 2, 2014  Cyberonics, Inc. ... from the ANTHEM-HF clinical study.  Results of the ... during a major European cardiology congress and concurrently ... show Autonomic Regulation Therapy (ART) in patients ... impaired heart function is safe, improves the heart,s ...
(Date:9/2/2014)... , Sept. 2, 2014  Based on ... treatment device market, Frost & Sullivan recognizes Novian ... & Sullivan Award for Technology Innovation Leadership. Novian ... fibroadenoma and malignant tumors with its proprietary technology, ... is a reliable, accurate, and easy-to-control ultrasound-guided thermo ...
Breaking Medicine Technology:Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 3Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 4Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 5ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 2ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 3ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 5Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 2Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 3Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 4Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 5
... , CINCINNATI , June 21 ... to its HARMONIC® line of surgical devices, the HARMONIC ... designed to extend the reach of surgeons for minimally ... (or 9cm) than the standard length HARMONIC ACE® device. ...
... today announced that six-month clinical follow-up data show the safety and ... (Sequent Please®, B.Braun) followed by implantation of the company,s Genous Bio-engineered ... , , ... single center, all-comers POTENT ( P aclitaxel-eluting ball O on and ...
Cached Medicine Technology:Ethicon Endo-Surgery Introduces HARMONIC ACE® 45 cm Curved Shears at ASMBS 2Ethicon Endo-Surgery Introduces HARMONIC ACE® 45 cm Curved Shears at ASMBS 3Data Show OrbusNeich's Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon 2Data Show OrbusNeich's Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon 3
(Date:9/2/2014)... The use of Xarelto (known generically ... at a rapid pace, even as Xarelto lawsuits ... the U.S., Bernstein Liebhard LLP reports. According to a ... a year of its 2011 launch, patients were just ... blood thinner that has been in use for several ...
(Date:9/2/2014)... in California, the percentage undergoing a double mastectomy increased ... not associated with a lower risk of death than ... the September 3 issue of JAMA . The ... one breast was associated with a higher risk of ... , Randomized trials have demonstrated similar survival for patients ...
(Date:9/2/2014)... September 02, 2014 The Dream2Walk Foundation along ... on Sept. 14th, 2014 during Spinal Cord Injury Awareness Month ... Lynn England, and Chuck Ligon. Linear Automotive will be there ... show. , Doors open at 2pm. The car show is ... one free pass to the concert. There will be trophies ...
(Date:9/2/2014)... -- Melatonin supplements did not reduce delirium in seniors ... found. Many older hospital patients experience the sudden, ... their normal sleep-wake cycle. A lack of the hormone ... but there has been little research into whether melatonin ... 378 patients, average age 84, who had hip fracture ...
(Date:9/2/2014)... LOS ANGELES (Sept. 2, 2014) Measuring the levels of ... suffer a sudden cardiac arrest, a heart rhythm disorder that ... new study, published online by the peer-reviewed journal Heart ... male sex hormone, were found in men who had a ... sex hormone, were strongly associated with greater chances of having ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2Health News:Study links sex hormone levels in the blood to risk of sudden cardiac arrest 2
... will develop one or more chronic health problems later in ... a study released Tuesday suggested. ,Dutch researchers ... cancer survivors found that 75 percent went on to develop ... reached their mid 20s, or early 30s at the latest. ...
... increased risk of jaw or facial bone deterioration or ... lesions, elevated levels of calcium in the blood, or ... found an association between the use of intravenous bisphosphonates ... condition in which poor blood supply to the area ...
... set to turn into a "no-smoking zone" by mid-July this year. ... be fully enforced from July 15 and will cover markets, restaurants ... users annually in the country. , ,The establishment says ... utilities will be allowed to set up a separate area for ...
... (IANS) Nearly 100 people have been bitten and injured by ... anti-rabies vaccines in the government hospitals to treat the patients. ... has attacked and injured villagers - including women and children ... of the district, about 200 km from here. ...
... program cuts diabetes risk and is more effective at ... overweight children. ,A family-based weight management ... was more successful at plummeting weight, body fat, BMI ... ,Mary Savoye-Desanti, research associate in Yale's Department of ...
... substantial progress in curbing the spread of polio with just 82 ... to 676 last year, says WHO. ,Of the ... Uttar Pradesh and 17 from Bihar, it says. ... with 585 for the same period in 2006,' said a WHO ...
Cached Medicine News:Health News:Childhood Cancer can Lead to Chronic Health Problems Later in Life: Study 2Health News:Bisphosphonate Increases the Risk of Jaw Bone Deterioration 2Health News:Chandigarh Set to Be No-smoking Zone from July 15 2Health News:Bright Bodies Weight Program Lowers Diabetes Risk, BMI in Obese Kids 2Health News:India Records Substantial Decline in Polio Cases 2
Female Compression VEST w/sleeves...
Male Support Brief...
Ideal for lower abdominal procedures. Comes with a left side separating zipper....
Arm Compression Garment...
Medicine Products: